Sinopharm Group Co. Ltd. (SHTDY)
OTC: SHTDY
· Real-Time Price · USD
12.46
0.14 (1.10%)
At close: Aug 15, 2025, 11:51 AM
Sinopharm Income Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 147.46B | 147.27B | 150.65B | 144.97B | 155.43B | 145.52B | 145.77B | 144.91B | 133.87B | 127.6B | 139.77B | 132.17B | 128.85B | 120.27B |
Cost of Revenue | 136.09B | 136.69B | 137.33B | 133.04B | 143.1B | 134.58B | 132.38B | 132.52B | 122.23B | 117.59B | 128.19B | 120.28B | 117.49B | 111.05B |
Gross Profit | 11.37B | 10.58B | 13.31B | 11.93B | 12.33B | 10.94B | 13.39B | 12.39B | 11.65B | 10.01B | 11.58B | 11.88B | 11.37B | 9.22B |
Operating Income | 5.13B | 3.39B | 7.76B | 3.46B | 5.82B | 4.01B | 8.02B | 3.53B | 5.75B | 3.76B | 6.67B | 5.24B | 5.86B | 3.21B |
Interest Income | n/a | 277.38M | 345M | n/a | 922.32M | 382.36M | 330.33M | 786.82M | 845.56M | 633.06M | 1.05B | 628.82M | 1.02B | 456.63M |
Pretax Income | 4.47B | 3.12B | 6.49B | 4.16B | 5.23B | 3.64B | 5.97B | 4.59B | 4.85B | 3.15B | 4.76B | 4.52B | 4.93B | 2.79B |
Net Income | 2.28B | 1.42B | 2.96B | 1.99B | 2.51B | 1.59B | 2.67B | 2.16B | 2.27B | 1.43B | 2.06B | 2.12B | 2.37B | 1.22B |
Selling & General & Admin | 6.87B | 6.84B | 7.06B | 5.73B | 7.05B | 6.64B | 7.81B | 5.66B | 6.39B | 5.99B | 6.16B | 5.73B | 6B | 5.76B |
Research & Development | 71.13M | 71.13M | 260.77M | 260.77M | 95.96M | 95.96M | 210.37M | 210.37M | 61.62M | 61.62M | 126.04M | 126.04M | 42.25M | 42.25M |
Other Expenses | -702.85M | 566.23M | n/a | 9.36M | n/a | n/a | 28.31M | -7.63M | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 6.24B | 7.18B | 6.48B | 417.63B | 6.18B | 6.92B | -366.01B | 379.04B | 5.95B | 6.23B | 5.77B | 6.73B | 5.42B | 5.97B |
Interest Expense | n/a | n/a | n/a | 512.59M | n/a | n/a | 1.27B | 449.56M | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | 4.27B | 4.21B | 4.82B | 4.21B | 4.3B | 4.13B | 4.8B | 4.14B | 3.98B | 3.8B | 3.77B | 4.06B | 3.85B | 3.75B |
Cost & Expenses | 142.33B | 143.87B | 143.82B | 139.95B | 149.28B | 141.5B | 138.7B | 139.22B | 128.17B | 123.82B | 133.95B | 127.01B | 122.91B | 117.02B |
Income Tax Expense | 972.43M | 724.85M | 1.54B | 987.09M | 1.14B | 827.84M | 1.44B | 1B | 1.05B | 721.61M | 1.21B | 1.04B | 1.06B | 629.22M |
Shares Outstanding (Basic) | 624.13M | 623.6M | 623.6M | 623.6M | 623.06M | 623.66M | 629.14M | 622.5M | 625.91M | 620.82M | 627.27M | 622.73M | 624.6M | 623.67M |
Shares Outstanding (Diluted) | 624.13M | 623.6M | 623.6M | 623.6M | 623.06M | 623.66M | 629.14M | 622.5M | 625.91M | 620.82M | 627.27M | 620.99M | 624.6M | 623.67M |
EPS (Basic) | 3.65 | 2.30 | 4.70 | 3.20 | 4.05 | 2.55 | 4.25 | 3.45 | 3.60 | 2.30 | 3.30 | 3.40 | 3.80 | 1.95 |
EPS (Diluted) | 3.65 | 2.30 | 4.70 | 3.20 | 4.05 | 2.55 | 4.25 | 3.45 | 3.60 | 2.30 | 3.30 | 3.40 | 3.80 | 1.95 |
EBITDA | 5.57B | 3.91B | 8.29B | 4.53B | 6.36B | 4.52B | 8.49B | 5.04B | 6.27B | 4.24B | 7.15B | 5.68B | 6.35B | 3.66B |
EBIT | 4.99B | 3.39B | 7.76B | 4.53B | 5.82B | 4.01B | 7.24B | 5.04B | 5.75B | 3.76B | 6.67B | 5.24B | 5.86B | 3.21B |
Depreciation & Amortization | 574.76M | 521.26M | 521.26M | 503.1M | 537.12M | 503.1M | 503.1M | 477.98M | 520.16M | 477.98M | 477.98M | 445M | 492.35M | 445M |